FDA Approves Abbott’s Xience Prime Coronary Stent

by Kathy Jones on  November 3, 2011 at 9:29 PM Corporate News   - G J E 4
US based pharmaceutical company Abbott Labs has revealed that its everolimus-eluting coronary stent has been approved by the Food and Drug Administration for the treatment of coronary artery disease.
 FDA Approves Abbott’s Xience Prime Coronary Stent
FDA Approves Abbott’s Xience Prime Coronary Stent

Abbott said that the stent, known as Xience Prime, is similar to its predecessor Xience V as it uses the same drug and biocompatible polymer but the company added that Xience Prime offers thinner struts which help it to maintain radial strength and thus offer better delivery.

Confirming the approval of the stent, the FDA said that its decision was based on the SPIRIT PRIME trial which tested the effectiveness of the stent in 500 patients with coronary artery disease.

The FDA revealed that the stent showed lower rates of target lesion failure and stent thrombosis at the end of one year.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like